U.S. Markets open in 5 hrs 4 mins

Tandem Diabetes Care’s Operational Performance

Kenneth Smith
Tandem Diabetes Care’s Operational Performance

For fiscal 2018 and 2019, Tandem Diabetes Care’s gross margins are expected at 47.13% and 51.78%, respectively, compared with 40% in fiscal 2017. The fiscal 2018 gross margins of peers DexCom (DXCM), Insulet (PODD), and Johnson & Johnson (JNJ) are expected at 64.29%, 65.59%, and 70.43%, respectively. Tandem Diabetes Care incurred selling, general, and administrative expenses of $29.51 million in the third quarter of 2018, versus $20.12 million in the third quarter of 2017.